MX389729B - Uso de antagonistas de aplnr e inhibidores de vegf para tratar trastornos oculares. - Google Patents

Uso de antagonistas de aplnr e inhibidores de vegf para tratar trastornos oculares.

Info

Publication number
MX389729B
MX389729B MX2019012985A MX2019012985A MX389729B MX 389729 B MX389729 B MX 389729B MX 2019012985 A MX2019012985 A MX 2019012985A MX 2019012985 A MX2019012985 A MX 2019012985A MX 389729 B MX389729 B MX 389729B
Authority
MX
Mexico
Prior art keywords
aplnr
ocular disorders
vegf inhibitors
treat ocular
aplnr antagonists
Prior art date
Application number
MX2019012985A
Other languages
English (en)
Other versions
MX2019012985A (es
Inventor
Eunice Cheung
Ivan B Lobov
Jingtai Cao
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2019012985A publication Critical patent/MX2019012985A/es
Publication of MX389729B publication Critical patent/MX389729B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente divulgación proporciona métodos para tratar, prevenir o reducir la gravedad de una enfermedad ocular. Los métodos de la presente divulgación comprenden administrar a un sujeto que lo necesita una composición terapéutica que comprende un antagonista de APLNR tal como un anticuerpo anti-APLNR en combinación con un antagonista del factor de crecimiento endotelial vascular (VEGF) (por ejemplo, aflibercept).
MX2019012985A 2017-05-06 2018-05-04 Uso de antagonistas de aplnr e inhibidores de vegf para tratar trastornos oculares. MX389729B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762502621P 2017-05-06 2017-05-06
PCT/US2018/031255 WO2018208625A1 (en) 2017-05-06 2018-05-04 Methods of treating eye disorders with aplnr antagonists and vegf inhibitors

Publications (2)

Publication Number Publication Date
MX2019012985A MX2019012985A (es) 2020-01-13
MX389729B true MX389729B (es) 2025-03-20

Family

ID=62555166

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012985A MX389729B (es) 2017-05-06 2018-05-04 Uso de antagonistas de aplnr e inhibidores de vegf para tratar trastornos oculares.

Country Status (9)

Country Link
EP (1) EP3618876A1 (es)
JP (1) JP7161494B2 (es)
KR (1) KR102667021B1 (es)
CN (1) CN110709104A (es)
AU (1) AU2018266324B2 (es)
EA (1) EA201992630A1 (es)
IL (1) IL270267B2 (es)
MX (1) MX389729B (es)
WO (1) WO2018208625A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4150766A4 (en) 2020-05-11 2023-10-25 Ascava, Inc. EXPLOITING PRIME DATA LOCATION TO EFFICIENTLY RETRIEVAL LOSSLESSLY REDUCED DATA USING A PRIME DATA SCREEN
CN115920057A (zh) * 2023-01-03 2023-04-07 中国科学院合肥物质科学研究院 靶向aplnr蛋白棕榈酰化修饰的多肽及其在癌痛治疗中的应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
JP2006523209A (ja) 2003-03-12 2006-10-12 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ アペリン組成物によって血管新生を調節するための方法
US7303748B2 (en) 2005-02-02 2007-12-04 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a VEGF inhibitor
PT2944306T (pt) 2006-06-16 2021-02-15 Regeneron Pharma Formulações antagonistas de vegf adequadas para administração intravitreal
US8946382B2 (en) 2009-02-27 2015-02-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Apelin peptides and methods of use
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
EP2734546A1 (en) 2011-07-18 2014-05-28 Amgen Inc. Apelin antigen-binding proteins and uses thereof
MY164611A (en) 2012-01-23 2018-01-30 Regeneron Pharma Stabilized formulations containing anti-ang2 antibodies
US9593153B2 (en) 2012-04-11 2017-03-14 Inserm (Institut National De La Sante Et De La Recherche Medicale) Modified apelin polypeptides
JP5775851B2 (ja) 2012-06-27 2015-09-09 東京エレクトロン株式会社 塗布装置および塗布液充填方法
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
AU2014236451B2 (en) * 2013-03-14 2018-08-09 Regeneron Pharmaceuticals, Inc. Apelin fusion proteins and uses thereof
JP6483117B2 (ja) * 2013-11-20 2019-03-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ａｐｌｎｒモジュレーター及びその使用
CA2942940A1 (en) 2014-03-20 2015-09-24 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of compounds inhibiting apelin / apj / gp130 signaling for treating cancer
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
KR102725051B1 (ko) * 2015-09-23 2024-11-04 제넨테크, 인크. 항-vegf 항체의 최적화된 변이체들

Also Published As

Publication number Publication date
IL270267B1 (en) 2024-02-01
WO2018208625A1 (en) 2018-11-15
CN110709104A (zh) 2020-01-17
CA3062418A1 (en) 2018-11-15
KR102667021B1 (ko) 2024-05-21
JP7161494B2 (ja) 2022-10-26
JP2020518641A (ja) 2020-06-25
KR20200004366A (ko) 2020-01-13
EA201992630A1 (ru) 2020-04-29
IL270267A (es) 2019-12-31
IL270267B2 (en) 2024-06-01
MX2019012985A (es) 2020-01-13
EP3618876A1 (en) 2020-03-11
AU2018266324B2 (en) 2024-02-01
AU2018266324A1 (en) 2019-11-28

Similar Documents

Publication Publication Date Title
CO2017004715A2 (es) Métodos y formulaciones para tratar enfermedades vasculares de los ojos
MX2024013963A (es) Un antagonista de il-4r util para el tratamiento o la prevencion del asma
CL2017002527A1 (es) Uso de agonistas de receptor de péptido formilo 2 para tratar enfermedades inflamatorias oculares. (divisional de solicitud n°2485-2015).
UY35313A (es) Antiadhesion de leucocitos para mitigar los potenciales eventos adversos causados por los dominios de unión específicos de cd3
AR107303A1 (es) Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit
CL2019002850A1 (es) Terapias combinadas dirigidas a pd-1, tim-3, y lag-3.
MX2021013327A (es) Anticuerpo anti-receptor cgrp para usarse en tratar o prevenir dolor de cabeza por migra?a.
CL2020002774A1 (es) Tratamiento combinado de fibrosis y/o angiogénesis ocular
MX2016000364A (es) Metodos para tratar o prevenir afecciones oftalmologicas.
MX2017016655A (es) Formulaciones oftalmicas de inhibidores de tirosina quinasa, metodos de uso de las mismas y metodos de preparacion de las mismas.
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CL2019002470A1 (es) Combinaciones de un derivado de 4-pirimidinsulfamida con ingredientes activos para el tratamiento de enfermedades relacionadas con endotelina.
CO2018014010A2 (es) Anticuerpos a la alfa-sinucleína y usos de los mismos
MX2018002990A (es) Uso de la akkermansia pasteurizada para tratar trastornos metabolicos.
MX2016000271A (es) Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r.
MX2018015724A (es) Metodos de tratamiento de cancer de mama que expresa el receptor de androgenos (ar+).
MX2016007111A (es) Inhibidores de tirosina quinasa de bruton.
MX2017000627A (es) Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe).
MX2018005715A (es) Uso de antagonistas del receptor ep4 para el tratamiento de cancer de higado asociado con nash.
UY34116A (es) El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico
CL2017001756A1 (es) Régimen de dosificación para antagonistas de madcam.
MX2021004755A (es) Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrizacion de heridas y la recuperacion posoperatoria.
CO2021015793A2 (es) Métodos para tratar o prevenir el asma mediante la administración un antagonista de il-33
EA201692402A1 (ru) Лекарственные формы для местного применения и их использование
MX2017011885A (es) Uso de antagonistas de receptores de glucocorticoides en combinacion con glucocorticoides para tratar la insuficiencia adrenal.